Moxonidine, a selective imidazoline/α2 adrenergic receptor agonist, synergizes with morphine and deltorphin II to inhibit substance P-induced behavior in mice

Pain

Volumn 84, Issue 1, 2000, Pages 13-20

  Fairbanks, Carolyn A ^a   Posthumus, Ivan J ^a   Kitto, Kelley F ^a   Stone, Laura S ^a   Wilcox, George L ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Adrenergic; Antinociception; Moxonidine; Opioid; Spinal; Synergy

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; DELTORPHIN; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; MORPHINE; MOXONIDINE; SUBSTANCE P;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; INTRATHECAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AGGRESSION; ANIMALS; ANTIHYPERTENSIVE AGENTS; DRUG SYNERGISM; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; IMIDAZOLES; INJECTIONS, SPINAL; MALE; MICE; MICE, INBRED ICR; MORPHINE; OLIGOPEPTIDES; PAIN; RECEPTORS, ADRENERGIC, ALPHA-2; SPINAL CORD; SUBSTANCE P;

EID: 0033992159     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(99)00171-2     Document Type: Article

References (47)

1. Armah I.B., Stenzel W. BE-5895, a new clonidine-type antihypertensive aminopyrimidine derivative. Naunyn Schmiedebergs Arch Pharmacol. 316:1981;R-42.
2. Codd E.E., Press J.B., Raffa R.B. Alpha 2-adrenoceptors vs. imidazoline receptors: implications for alpha 2-mediated analgesia and other non-cardiovascular therapeutic uses. Review, Life Sci. 56:1995;63-74.
3. Eisenach J.C., Lysak S.Z., Viscomi C.M. Epidural clonidine analgesia following surgery: phase I. Anesthesiology. 71:1989;640-646.
4. Eisenach J.C., Rauck R.L., Buzzanell C., Lysak S.Z. Epidural clonidine analgesia for intractable cancer pain: phase I. Anesthesiology. 71:1989;647-652.
5. Eisenach J.C., D'Angelo R., Taylor C., Hood D.D. An isobolographic study of epidural clonidine and fentanyl after cesarean section. Anesthesia and Analgesia. 79:1994;285-290.
6. Eisenach J.C., DuPen S., Dubios M., Miguel R., Allin D. Epidural clonidine analgesia for intractable cancer pain. 61:1995;391-399.
7. Fairbanks C.A., Wilcox G.L. Moxonidine, a selective alpha 2 adrenergic and imidazoline receptor agonist, produces spinal antinociception in mice. J Pharmacol Exp Ther. 290:(1):1999;403-412.
8. Fairbanks C.A., Wilcox G.L. Spinal antinociceptive synergism between morphine and clonidine persists in mice made acutely or chronically tolerant to morphine. J Pharmacol Exp Ther. 288:1999;1107-1116.
9. Gessner P.K., Cabana B.E. A study of the interaction of the hypnotic effects and of the toxic effects of chloral hydrate and ethanol. J Pharmacol Exp Ther. 174:1970;247-259.
10. Glynn C.J., Jamous M.A., Teddy P.J., Moore R.A., Lloyd J.W. Role of spinal noradrenergic system in transmission of pain in patients with spinal cord injury. Lancet. 2:(85):1986;249-250.
11. Harada Y., Nishioka K., Kitahata L.M., Kishikawa K., Collins J.G. Visceral antinociceptive effects of spinal clonidine combined with morphine, [D-Pen2, D-Pen5] enkephalin, or U50,488H. Anesthesiology. 83:1995;344-352.
12. Hunter J.C., Fontana D.J., Hedley L.R., Jasper J.R., Lewis R., Link R.E., Secchi R., Sutton J., Eglen R.M. Assessment of the role of alpha2-adrenoceptor subtypes in the antinociceptive, sedative and hypothermic action of dexmedetomidine in transgenic mice. Br J Pharmacol. 122:1997;1339-1344.
13. Hylden J.L.K., Wilcox G.L. Intrathecal morphine in mice: a new technique. Eur J Pharmacol. 67:1980;313-316.
14. Hylden J.L.K., Wilcox G.L. Intrathecal substance P elicits a caudally-directed biting and scratching behavior in mice. Brain Res. 217:1981;212-215.
15. Hylden J.L.K., Wilcox G.L. Pharmacological characterization of substance P-induced nociception in mice: modulation by opioid and noradrenergic agonists at the spinal level. J Pharmacol Exp Ther. 226:1983;398-404.
16. Janumpalli S., Butler L.S., MacMillan L.B., Limbird L.E., McNamara J.G. A point mutation (D79N) of the α2A adrenergic receptor abolishes the antiepileptogenic. J. Neurosci. 1998;2004-2008.
17. Kraft K., Vetter H. Twenty-four-hour blood pressure profiles in patients with mild-to-moderate hypertension: moxonidine versus captopril. J. Cardiovasc Pharmacol. 24:1994;S29-S33.
18. Küppers H.E., Jager B.A., Luszick J.H., Grave M.A., Hughes P.R., Kaan E.C. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertension. 15:1997;93-97.
19. Lakhlani P.P., Macmillan L.B., Guo T.Z., Mccool B.A., Lovinger D.M., Maze M., Limbird L.E. Substitution of a mutant alpha(2a)-adrenergic receptor via hit and run gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. Proc Natl Acad Sci USA. 94:1997;9950-9955.
20. Loewe S. The problem of synergism and antagonism of combined drugs. Arzeim Forsch. 3:1953;285-290.
21. Mendez R., Eisenach J.C., Kashtan K. Epidural clonidine analgesia after cesarean section. Anesthesiology. 73:1990;848-852.
22. Mizobe T., Maghsoudi K., Sitwala K., Tianzhi G., Ou J., Maze M. Antisense technology reveals the alpha2A adrenoceptor to be the subtype mediating the hypnotic response to the highly selective agonist, dexmedetomidine, in the locus coeruleus of the rat. J Clin Investigation. 98:1996;1076-1080.
23. Monasky M.S., Zinsmeister A.R., Stevens C.W., Yaksh T.L. Interaction of intrathecal morphine and ST-91 on antinociception in the rat: dose response analysis, antagonism and clearance. J Pharmacol Exp Ther. 254:1990;383-392.
24. Ollivier J.P., Christen M.O. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience. J Cardiovasc Pharmacol. 24:1994;S39-S48.
25. Omote K., Kitahata L.M., Collins J.G., Nakatani K., Nakagawa I. Interaction between opiate subtype and alpha-2 adrenergic agonists in suppression of noxiously evoked activity of WDR neurons in the spinal dorsal horn. Anesthesiol. 74:1991;737-743.
26. Ossipov M., Harris S., Lloyd P., Messineo E. An isobolographic analysis of the antinociceptive effect of systemically and intrathecally administered combinations of clonidine and opiates. J Pharmacol Exp Ther. 255:1990;1107-1116.
27. Ossipov M., Harris S., Lloyd P., Messineo E., Lin B., Bagley J. Antinociceptive interaction between opioids and medetomidine: systemic additivity and spinal synergy. Anesthesiology. 73:1990;1227-1235.
28. Ossipov M., Lozito R., Messineo E., Green J., Harris S., Lloyd P. Spinal antinociceptive synergy between clonidine and morphine, U69593, and DPDPE: isobolographic analysis. Life Sci. 47:1990;71-76.
29. Ossipov M.H., Lopez Y., Bian D., Nichols M.L., Porreca F. Synergistic antinociceptive interactions of morphine and clonidine in rats with nerve-ligation injury. Anesthesiology. 86:1997;1-9.
30. Paalzow L. Analgesia produced by clonidine in mice and rats. J Pharmacy Pharmacol. 26:1974;361-363.
31. Piletz J.E., Zhu H., Chikkala D.N. Comparison of ligand binding affinities at human I-1-Imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J Pharmacol Exp Ther. 279:1996;694-702.
32. Plänitz V. Crossover comparison of moxonidine and clonidine in mild to moderate hypertension. Eur J Clin Pharmacol. 27:1984;147-152.
33. Plänitz V. Intraindividual comparison of moxonidine and prazosin in hypertensive patients. Eur J Clin Pharmacol. 29:1986;645-650.
34. Rauck R.L., Eisenach J.C., Jackson K., Young L.D., Southern J. Epidural clonidine treatment for refractory reflex sympathetic dystrophy. Anesthesiology. 79:1993;1163-1169.
35. Reddy S.V., Yaksh T.L. Spinal noradrenergic terminal system mediates antinociception. 189:1980;391-401.
36. Reddy S.V.R., Maderdrut J.L., Yaksh T.L. Spinal cord pharmacology of adrenergic agonist-mediated antinociception. J Pharmacol Exp Ther. 213:1980;525-533.
37. Roerig S.C. Decreased spinal morphine/clonidine antinociceptive synergism in morphine-tolerant mice. Life Sciences. 56:1995;PL115-PL122.
38. Roerig S.C., Fujimoto J.M. Multiplicative interaction between intrathecally and intracerebroventricularly administered mu opioid agonists but limited interactions between delta and kappa agonists for antinociception in mice. J Pharmacol Exp Ther. 249:1989;762-768.
39. Roerig S., Lei S., Kitto K., Hylden J.L.K., Wilcox G.L. Spinal interactions between opioid and noradrenergic agonists in mice: Multiplicitivity involves δ and α2 receptors. J Pharmacol Exp Ther. 262:1992;365-374.
40. Siddall P.J., Gray M., Rutkowski S., Cousins M.J. Intrathecal morphine and clonidine in the management of spinal cord injury pain: a case report. Pain. 59:1994;147-148.
41. Spaulding T.C., Fielding S., Venafro S.S., Lal H. Antinociceptive activity of clonidine and its potentiation of morphine analgesia. Eur J Pharmacol. 58:1979;19-25.
42. Stone L.S., Macmillan L.B., Kitto K.F., Limbird L.E., Wilcox G.L. The alpha(2a) adrenergic receptor subtype mediates spinal analgesia evoked by alpha(2) agonists and is necessary for spinal adrenergic-opioid synergy. J Neurosci. 17:1997;7157-7165.
43. Takano Y., Yaksh T.L. Chronic spinal infusion of dexmedetomidine ST-91 and clonidine: spinal alpha2 adrenoceptor subtypes and intrinsic activity. J Pharmacol Exp Ther. 264:1993;327-335.
44. Tallarida R.J., Murray R.B. Manual of pharmacologic calculations with computer programs. 1987;Springer-Verlag, New York.
45. Tallarida R.J. Statistical analysis of drug combinations for synergism. Pain. 49:1992;93-97.
46. Wilcox G.L., Carlsson K.H., Jochim A., Jurna I. Mutual potentiation of antinociceptive effects of morphine and clonidine in rat spinal cord. Brain Res. 405:1987;84-93.
47. Yaksh T.L., Reddy S.V. Studies in the primate on the analgetic effects associated with intrathecal actions of opiates, alpha-adrenergic agonists and baclofen. Anesthesiology. 54:1981;451-467.